---
figid: PMC9697247__pharmaceutics-14-02476-g002
pmcid: PMC9697247
image_filename: pharmaceutics-14-02476-g002.jpg
figure_link: /pmc/articles/PMC9697247/figure/pharmaceutics-14-02476-f002/
number: Figure 2
figure_title: ''
caption: Different approaches to enhance or activate Wnt signaling. (A) Anti-LRP5
  P6C.51.61 antibody. (B) FZD4-LRP5 bispecific F4.L5.13 antibody. (C) FZD4-LRP5 bispecific
  SZN-413 antibody. The drawings are for illustration purpose only, not drawn to scale
  nor are the epitopes/binding regions precisely mapped.
article_title: Selective Activation of the Wnt-Signaling Pathway as a Novel Therapy
  for the Treatment of Diabetic Retinopathy and Other Retinal Vascular Diseases.
citation: Huy Nguyen, et al. Pharmaceutics. 2022 Nov;14(11):2476.
year: '2022'

doi: 10.3390/pharmaceutics14112476
journal_title: Pharmaceutics
journal_nlm_ta: Pharmaceutics
publisher_name: MDPI

keywords:
- Wnt
- diabetic retinopathy
- Norrin
- FZD4
- LRP5
- therapeutics
- BRB
- BBB
- WNT mimetic

---
